Navigation Links
Muscular Dystrophy Market Clinical Trials Report for H2 2015
Date:12/22/2015

PUNE, India, December 22, 2015 /PRNewswire/ --

ReportsnReports.com adds "Muscular Dystrophy Global Clinical Trials Review, H2, 2015" market research report that provides an overview of muscular dystrophy clinical trials scenario, enhances decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

This report provides top line data relating to the clinical trials on Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Complete report on Muscular Dystrophy Clinical Trials spread across 79 pages, supported with 23 tables and 24 figures is now available at http://www.reportsnreports.com/reports/445331-muscular-dystrophy-global-clinical-trials-review-h2-2015.html .

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report provides a snapshot of the global clinical trials landscape with top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status and reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company. The report also provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment, enrollment trends for the past five years and latest news for the past three months.

Order a copy of Muscular Dystrophy Global Clinical Trials Review, H2, 2015 market research report at http://www.reportsnreports.com/purchase.aspx?name=445331 .

Reasons to buy 

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Another newly published market research report titled on EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2023 provides an overview of the risk factors, comorbidities, and the global and historical trends for DMD in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DMD and Becker Muscular Dystrophy (BMD) in men, segmented by age (in 10-year age groups beginning at 0 years and ending at =40 years for cases of DMD with a special focus on the subgroup of ages 5-13 years, and in 15-year age groups beginning at 0 years and ending at =75 years for cases of BMD) in these markets. Additionally, the diagnosed prevalent cases of DMD (all ages) are further segmented by the applicability of exon skipping therapies (exons 51, 45, 53, and 44) and nonsense mutations. Duchenne Muscular Dystrophy market research report of 51 pages is available at http://www.rnrmarketresearch.com/epicast-report-duchenne-muscular-dystrophy-epidemiology-forecast-to-2023-market-report.html .

Explore more reports on Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml



'/>"/>
SOURCE ReportsnReports
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Parent Project Muscular Dystrophy Returns to Baltimore for Annual Connect Conference; Presenters Include FDA, Major Pharma
2. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
3. New Evidence Published in Muscle and Nerve on Measuring 6-Minute Walk Distance in Duchenne Muscular Dystrophy
4. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
5. Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
6. Isis Pharmaceuticals to Investigate a Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
7. Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
8. Orally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits In Mouse Models Of Spinal Muscular Atrophy
9. Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy
10. Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
11. PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):